H.C. Wainwright analyst Mitchell Kapoor has reiterated their bullish stance on KYTX stock, giving a Buy rating yesterday.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Mitchell Kapoor has given his Buy rating due to a combination of factors that highlight the potential of Kyverna Therapeutics, Inc. The company’s KYV-101 has shown promising results in progressive multiple sclerosis (MS), demonstrating early functional gains and CNS penetration, which adds potential upside not yet included in the current price target. The valuation of Kyverna is considered conservative, as it does not fully reflect the opportunities in myasthenia gravis (MG) or stiff-person syndrome (SPS), providing investors with “free” exposure to these areas.
Furthermore, the company’s financial position is strong, with a cash runway extending into 2027 and over 100 patients treated without high-grade adverse events. The upcoming 4Q25 MG Phase 2 interim readout is expected to provide further insights into the efficacy of KYV-101, with previous compassionate-use cases showing durable remission. These factors, combined with the potential for a single infusion therapy to offer multi-year remission, make Kyverna’s stock an attractive buy according to Kapoor.
According to TipRanks, Kapoor is an analyst with an average return of -7.9% and a 40.00% success rate. Kapoor covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals, Sarepta Therapeutics, and Summit Therapeutics.
In another report released yesterday, Morgan Stanley also reiterated a Buy rating on the stock with a $20.00 price target.